FLT3 and acute myeloid leukemia: Moreover, entinostat induced degradation of Fms-like tyrosine kinase 3 (FLT3) through inhibition of Hsp90 chaperone activity in AML cells, suggesting that this inhibitor may be useful for treating patients with FLT3 mutations, a common genetic alteration in AML (reviewed in [24]).